INTERCEPT PHARMACEUTICALS, INC. Litigation

Apr 20, 2022

No Appeal- Closed

Mar 21, 2022

Motion to Dismiss Granted

The court has granted the defendants' request to dismiss the lawsuit. Depending on the court's decision, the plaintiffs may be allowed to file an updated complaint or pursue an appeal.

Apr 26, 2021

Motion to Dismiss

After reviewing the complaint(s) filed by plaintiffs, defendants have filed a motion requesting that the court dismiss some or all of the plaintiffs' claims. In a motion to dismiss, defendants might challenge the validity of plaintiffs' claims or adequacy of plaintiffs' pleadings. Once a motion to dismiss is filed, the judge will make a decision on whether part or all of the case should be dismissed or the case can proceed as alleged.

Mar 11, 2021

First Amended Complaint

A new complaint has been filed on behalf of certain investors in INTERCEPT PHARMACEUTICALS, INC.. Amended complaints may contain additional facts, parties, allegations, a change in the class definition, etc.

Feb 8, 2021

Scheduling Order

Jan 25, 2021

Appointment of Lead Plaintiff

The court has appointed a lead plaintiff to represent the interests of investors in the lawsuit. The lead plaintiff works with the attorneys handling the case, helps oversee the litigation, and represents the interests of the proposed class.

Jan 5, 2021

Scheduling Order

Nov 5, 2020

First Filed Complaint

A securities fraud class action complaint has been filed on behalf of certain investors in INTERCEPT PHARMACEUTICALS, INC..